17 reports

Viral vectors dominate the gene delivery systems with maximum number of approved drugs.

  • Gene Therapy
  • World
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Genzyme Corporation

Gene Therapy R& D and Revenue Forecasts 2018-2028 ##.

  • Gene Therapy
  • Medical Biotechnology
  • World
  • Forecast

ONE APPROVED GENE THERAPY, NEOVASCULGEN, USED PLASMID DNA; HOWEVER, THE DRUG IS PRESENTLY APPROVED ONLY IN RUSSIA AND UKRAINE.

  • Gene Therapy
  • World
  • Market Size
  • Supply
  • Sanofi S.A.

No drug-related serious adverse events related to the drug were reported in subjects in the cohort receiving ABO-## (Cohort ##: ##E## vg/ kg) through over ##, ## cumulative follow-up days.

  • Gene Therapy
  • Therapy
  • World
  • Product Initiative
  • Abeona Therapeutics, Inc.

The company' s proprietary plaftform is used in drug delivery, rapid detection of biowarfare agents, rapid detection of pesticides and immunogenicity tests for biotherapeutics among others.

  • Gene Therapy
  • Type 2 Diabetes
  • Wound Care
  • World
  • ProMetic Life Sciences Inc.

(ArmaGen) received three new patents on IgG-neurotrophin fusion proteins for targeted brain drug delivery across the human blood-brain barrier (BBB) from US Patent Office.

  • Gene Therapy
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative

J-Brain Cargo® enables crossing of a drug compound to the BBB but also to skeletal muscle, where drug delivery is said to be challenging.

  • Gene Therapy
  • Therapy
  • World
  • Product Initiative
  • Amicus Therapeutics
  • ACROMEGALY - PIPELINE BY ANTISENSE THERAPEUTICS LTD, H1 2018

It provides a drug delivery technology that allows the non invasive delivery of a broad range of protein, peptide, nucleotide, non peptide and other small and large molecule drugs.

  • Gene Therapy
  • Hormone
  • Therapy
  • World
  • Product Initiative

It also offers drug delivery mechanisms for treating diseases of the eye.

  • Eye Disease
  • Gene Therapy
  • World
  • Product Initiative
  • EyeGate Pharmaceuticals, Inc.

Gene therapy for MPS IIIA involves a one-time delivery of a normal copy of the heparan N-sulfatase (sulfamidase) gene to the brain, fallowing the brain to continually synthesize and secrete enough enzyme to halt the disease.

  • Gene Therapy
  • Therapy
  • World
  • Product Initiative
  • Abeona Therapeutics, Inc.
  • Licensing and Collaboration
  • R&D Progress

Currently, Soleo Health administers the patient care services and delivery of nine limited distribution drugs across multiple therapeutic classes.

  • Blood Disease
  • Gene Therapy
  • World
  • Company
  • Product Initiative

ABBVIE DISCOVERS AND DEVELOPS NOVEL MEDICINES BASED ON PROTEIN-BASED AND TARGETED DRUG DELIVERY TECHNOLOGIES.

  • Gene Therapy
  • Monoclonal Antibody
  • Psychotic Disorder
  • World
  • Product Initiative

As a result, delivery of the drug into the brain was confirmed.

  • Gene Therapy
  • Genomics
  • Therapy
  • World
  • Product Initiative

IV delivery of ABO- ## induced clearance of lysosomal GAG storage in the CNS and somatic tissues The Phase I/ II study will involve two dose cohorts involving intravenous administration of the drug candidate and with a primary objective being determination of safety of the

  • Gene Therapy
  • Therapy
  • World
  • Product Initiative
  • Abeona Therapeutics, Inc.

The company provides RNAi-targeted drugs, delivery systems and DsiRNA molecules.

  • Cell Therapy
  • Gene Therapy
  • World
  • Product Initiative
  • Galectin Therapeutics Inc.

The company provides RNAi-targeted drugs, delivery systems and DsiRNA molecules.

  • Digestive System Disorder
  • Gene Therapy
  • World
  • Company
  • Product Initiative

The company said that current drug licensed for treatment of the disease is one of the most expensive drugs in the world.

  • Endocrine Disease
  • Gene Therapy
  • Therapy
  • World
  • Product Initiative